drugset / Trial / NCT03611738
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Non-randomizedSequentialOpen-labelTreatment
Summary
The main purpose of this study is to find out what effects (good and bad) ceritinib (Zykadia®) used in combination with docetaxel (Taxotere®) will have on participants and their cancer. The results will help to determine the best safe dose of the combination of the medications Ceritinib (Zykadia®) and docetaxel (Taxotere®) and to find out if this combination of drugs will help people that have this type of Non-small Cell Lung Cancer (NSCLC).
Timeline
- Start
- 2019-02-01
- Primary completion
- 2025-04-28
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceritinib | Small molecule | 150 mg | Oral |
| Subject | Ceritinib | Small molecule | 300 mg | Oral |
| Subject | Ceritinib | Small molecule | 450 mg | Oral |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |